key: cord-0729725-5tp5k8kt authors: Shin, H. J.; Chow, R.; Noh, H.; Lee, J.; Choi, Y.-G. title: The association between immunosuppressants use and COVID-19 adverse outcome: National COVID-19 cohort in South Korea date: 2021-08-20 journal: nan DOI: 10.1101/2021.08.17.21262183 sha: e91b592f33ad964020c38ce60e18bdf1d2cd1700 doc_id: 729725 cord_uid: 5tp5k8kt Background: There is uncertainty of the effect of immunosuppression, including corticosteroids, before COVID-19 infection on COVID-19 outcomes. The aim of this study was to investigate the relationship between prehospitalization immunosuppressants use (exposure), and COVID-19 patient outcomes. Methods: We conducted a population-based retrospective cohort study using a nationwide healthcare claims database of South Korea as of May 15, 2020. Confirmed COVID-19 infection in hospitalized individuals aged 40 years or older were included for analysis. We defined exposure variable by using inpatient and outpatient prescription records of immunosuppressants from the database. Our primary outcome was a composite endpoint of all-cause death, intensive care unit (ICU) admission, and mechanical ventilation use. Inverse probability of treatment weighting (IPTW)-adjusted logistic regression analyses were used, to estimate odds ratio (OR) and 95% confidence intervals, comparing immunosuppressants users and non-users. Findings: We identified 4,349 patients, for which 1,356 were immunosuppressants users and 2,903 were non-users. Patients who used immunosuppressants were at increased odds of the primary outcome of all-cause death, ICU admission and mechanical ventilation use (IPTW OR 1.32; 95% CI: 1.06 - 1.63). Patients who used corticosteroids were at increased odds of the primary outcome (IPTW OR 1.33; 95% CI: 1.07 - 1.64). Interpretation: We support the latest guidelines from the CDC, that people on immunosuppressants are at high risk of severe COVID-19 and immunocompromised people may need booster COVID-19 vaccinations. In December 2019, an outbreak of a novel coronavirus was reported in Wuhan, China, which was later named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses 1,2 . The SARS-Cov-2 virus rapidly spread around the world, causing the COVID-19 disease in infected patients; on March 12, 2020, the World Health Organization (WHO) officially declared COVID-19 a pandemic 3 . As the scientific community raced to find possible active agents for treatment and cure of COVID-19, supportive care therapies were developed and tested 3, 4 . Immunosuppressants, specifically corticosteroids, were employed, as it could help COVID-19 patients by mitigating cytokine storms 5 . But, there are concerns that it can worsen viral shedding, and increase mortality due to COVID-19 6 . The current WHO clinical guidelines, as of November 20, 2020, provides a strong recommendation for corticosteroids use in severe and critical patients with COVID-19 disease 7 . However, in patients with mild to moderate COVID-19 infection who do not require oxygen support, corticosteroids use was associated with a trend towards higher mortality, although not statistically significant in the RECOVERY trial (17.8% vs 14%; RR 1.19 and 95% CI: 0.92-1.55) 8 . As a result, there is uncertainty of the effect of immunosuppression, including corticosteroids started before COVID-19 infection, on COVID-19 outcomes since patients on immunosuppression could have any spectrum of COVID-19 disease, from asymptomatic to critical COVID-19 infection. It is possible that patients with non-severe COVID-19 infection could receive harm from baseline corticosteroids use. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint The aim of this study was to investigate the relationship between immunosuppressants use, including corticosteroids, and COVID-19 patient outcomes. The Health Insurance Review and Assessment Service (HIRA) of South Korea is the sole nationwide government agency that operates a fee-for-service reimbursement system, which covers 98% of the Korean population. Its administrative claims database includes the beneficiary's sociodemographic characteristics, healthcare utilization history, diagnosis results (International Classification of Diseases, 10 th Revision), as well as prescription from both inpatient and outpatient settings. On March 27, 2020, the #OpenData4COVID19 project by the Ministry of Health and Welfare (MOHW) of Korea released a patient-level, deidentified COVID-19 data based on the HIRA insurance claims database, which is the first nationwide dataset of COVID-19 patients. The HIRA COVID-19 database included data for all individuals who received a reverse transcription-polymerase chain reaction (RT-PCR) test for COVID-19 as of May 15, 2020, which was linked to their claims data for the previous three years. Bioethics Committee designated by the MOHW, which waived the requirement of informed consent due to retrospective study design and anonymity of the HIRA database (IRB # P01-2020-1262-001. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The HIRA data consisted of 234,427 individuals who were tested for SARS-CoV-2 between January 1, 2020 and May 15, 2020. 7,590 were identified positive for COVID-19, as designated by the coding in the #OpenData4COVID19 project (Supplementary Material 2). 4,610 individuals were aged 40 years or older. We excluded those who were less than 40 years old, as it is unlikely that these younger individuals would experience severe COVID-19 outcomes. For precise outcome measurements, we further restricted to individuals who were hospitalized for COVID-19, resulting in 4,349 individuals in our study cohort ( Figure 1 ). The cohort entry date was defined as the admission date of COVID-19 hospitalization. In South Korea, individuals who were confirmed COVID-19 positive were required hospitalization until full recovery, defined by the cessation of fever without medication use and two negative test results within 24 hours 9 . However, there were a small number of confirmed COVID-19 patients who were not hospitalized due to the temporal shortage of health facilities. We classified individuals who had inpatient and outpatient prescription records of immunosuppressants at least once within 120 days prior to the cohort entry (ascertainment window: -120d to 0d) as immunosuppressants users. Other individuals were defined as nonusers. Among immunosuppressants, corticosteroids were assessed upon as separate exposure in sensitivity analysis. Our definition follows an intention-to-treat approach. Immunosuppressants were identified by the anatomical therapeutic chemical (ATC) codes (Supplementary Material 2). Our primary outcome was a composite endpoint of all-cause death, intensive care unit (ICU) admission, and mechanical ventilation use. As secondary outcomes, we evaluated the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint individual components, of the primary composite endpoint. In-hospital ICD-10 diagnostic codes and the national procedure codes were used to define the outcomes (Supplementary Material 2). We measured these study outcomes between the cohort entry date through the end of follow-up (discharge, or end of study). We considered sociodemographic and clinical factors as potential confounders. We included sex, age (in years), age square and health insurance type at cohort entry for sociodemographic factors. Clinical factors consisted of 20 comorbidities and 12 co-medications uses. The complete list of clinical factors and their working definitions is described in Supplementary Material 2. We defined comorbidity variables using in-hospital ICD-10 diagnostic codes, with an index period from 3 years prior (-1080d) through the start of the evaluation of exposure (-120d). When defining malignancy, we additionally employed the expanded benefit coverage codes, to minimize false-positive classification. For co-medication use, we used in/out-hospital ATC codes with an index period from -240d to -120d. We described baseline characteristics for immunosuppressants users and non-users as counts with percentage (for categorical variables) and means with standard deviations (for continuous variables). We summarized distributional imbalances between two groups by absolute standardized difference (aSD) for each variable. Empirically, aSD  0.1 is preferred for balance between groups. For outcome analysis, we employed the inverse probability of treatment weight (IPTW) approach 10,11 , based on propensity scores (PS), the probability for an individual to receive All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint immunosuppressants. We estimated PS by a multivariable logistic regression that included all confounders in Table 1 as predictors. Every individual was weighted by either 1/PS (the immunosuppressants users) or 1/(1-PS) (non-users). This led to a balanced pseudo-population. Then, we fitted weighted univariate logistic regression models to estimate odds ratio (OR) with 95% confidence intervals (CI) for the association effect of immunosuppressants on each outcome. In addition, for comparison purposes, we fitted unweighted univariate logistic regression models and unweighted multivariate logistic regression models, adjusting for age, sex, insurance type, history of diabetes and history of hypertension. We conducted a subgroup analysis for the risk of the primary outcome. We considered stratifications by the following: (1) sex; (2) age, classified into groups with age < 65 years and ≥ 65 years; (3) the history of autoimmune disease, cancer and HIV, and (4) the history of autoimmune disease. For each subgroup analysis, we conducted a multivariate IPTW-weighted logistic regression that includes the exposure (immunosuppressants use), stratification variable and the interaction of those two. We obtained the p-value of the interaction term (p for interaction). For the weight used in subgroup analyses, we recalculated PS using multivariate logistic regression. We investigated the sensitivity of results against the scope of working definitions. First, we redefined the study population by those who were aged ≥ 40 years and confirmed positive, which relaxes the restriction of hospitalization. Second, to exclude individuals who used immunosuppressants for a short period but stopped prior to hospitalization, we narrowed down the window of ascertaining exposure, from 120 days to 90 days. Third, we narrowed down the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint definition of the exposure variable from immunosuppressants use to corticosteroids use. For each change of the settings, we repeated our main analysis. To examine the sensitivity of results against the selection of statistical tools, the following alternative approaches were considered. First, we excluded subjects with extreme PS values, that is, PS < 0.025 or PS > 0.975 (IPTW with trimming). Second, we additionally included the fitted PSs to other covariates in our unweighted multivariable logistic regression model (outcome adjustment model). Third, we used the stabilized mortality ratio weight, defined as 1 for immunosuppressants users and PS(1 -PS) for non-users, in place of IPTW in our main model (SMR weighting). Finally, we considered a propensity score matching approach (PS matching). All statistical analyses were conducted using R 3.5.2. P-values less than 0.05 were considered statistically significant. ,349 patients were included in this study, for which 1,356 (31%) used immunosuppressants within 120 days of hospitalization for COVID-19. Users of immunosuppressants were older, and a larger proportion had hyperlipidemia and hypertension. A larger proportion of immunosuppressants users also used acetaminophen, systematic antibiotics, and NSAIDs (Table 1) . Patients who used immunosuppressants were at increased odds of the primary outcome of allcause death, ICU admission, mechanical ventilation use, MI, stroke and TIA (IPTW OR 1.32; 95% CI: 1.06 -1.63). When assessing the component outcomes individually, immunosuppressants users were only at higher odds of all-cause mortality -IPTW OR 1.63; 95% CI: 1.21 -2.26 ( Table 2 ). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint There exists no effect modification by age, sex, history of autoimmune diseases, cancer and HIV, and history of autoimmune disease ( Figure 2 ). The results of the sensitivity analysis remained consistent with the main analysis (Supplementary Material 3-6). When redefining the study population to include all confirmed patients with COVID-19 (IPTW OR 1.33; 95% CI: preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in This study reports on a nationwide cohort of South Korean COVID-19 patients. This dataset was completely enumerated, and statistically controlled for confounding using propensity scores. The results suggest that patients administered immunosuppressants were at increased odds of all-cause mortality, mechanical ventilation and ICU admission, Also, Anderson et al 19 reported contrary results to our paper, in that adverse outcomes were not associated with immunosuppressants use before COVID-19. However, their paper reported on a sicker patient population who might have received benefit from corticosteroids, whereas our analysis reports on a nationwide cohort of all patients admitted for COVID-19 to South Korean hospitals which include patients with non-severe COVID-19 infection. In South Korea, typically all COVID-19 patients were admitted to hospital even if they were asymptomatic or had mild symptoms, in an attempt to limit spread of the COVID-19 infection. As a result, our study provides a more complete picture with all spectrum of COVID-19 patients, from asymptomatic to critical COVID-19. As corticosteroids use is beneficial in patients with severe All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint to critical stage in COVID-19 infection and could possibly be harmful in patients with nonsevere COVID-19 infection, as seen from RECOVERY trial 8 , it comes as no surprise that our study results showing increased odds of primary outcome or mortality in immunosuppressants or corticosteroids user given that most of COVID-19 infections are non-severe 20 . Given our study results, we support booster COVID-19 vaccinations for immunocompromised people and urge caution around blanket-continuation of immunosuppressants for COVID-19 who were on immunosuppressants prior to COVID-19 diagnosis; patients might need to be assessed on a per-case basis, weighting the risk of adverse COVID-19 outcomes and benefits of continuing immunosuppressants. Consideration may need to be given to lower the degree of immunosuppression if a patient was on corticosteroids and has non-severe COVID-19 infection. There are several notable strengths of this study. As South Korea used a strict nationwide patient management system for COVID-19, the use of a population-based cohort mitigated any potential sampling bias issue. There could be very little chance of outcome misclassification since outcomes such as all-cause death and outcomes defined from procedures codes (i.e. ICU admissions and mechanical ventilation use) are unlikely to be misclassified in the main analysis restricted to hospitalized COVID-19 patients, given the cross-referencing of these records with national death records and reimbursement review processes, respectively. Consistent results across rigorous statistical methods including IPTW, PS matching, SMR and thorough sensitivity analyses suggest a robustness of our result. Additionally, including chronic comedications as confounders could have mitigated healthy user bias. This study was also not without limitations. We do not have data regarding the severity of COVID-19 at the time of COVID-19 diagnosis, which is a limitation of using claims data. In All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint addition, there may still exist residual confounding by confounders that are typically not captured in a claims database (e.g., body mass index, baseline blood pressure, laboratory test values). Also, our result is limited by the observational nature of our study design. In conclusion, our study of a large nationwide cohort of hospitalized COVID-19 patients in South Korea finds that use of immunosuppressants or corticosteroids increases the odds of allcause mortality, mechanical ventilation and ICU admissions. We support the latest guidelines perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Mean and standard deviation were reported for continuous variables. Frequency and percentage were reported for categorical variables. *Patients prescribed within 120 days prior to cohort entry were regarded as immunosuppressants users, and otherwise defined as non-users. §Weighted cohort using the inverse probability of treatment weighting (IPTW). #Immunosuppression includes HIV, transplanted status, transplant rejection, noninfectious enteritis and colitis, ulcerative colitis, and Crohn's disease. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint Figure 1 . Nationwide population-based cohort study design using the HIRA and KDCA database of South Korea for the entire South Korean population of 50 million inhabitants. Hospitalized patients aged >= 40 who used immunosuppressants within 120 days before COVID-19 test were classified as immunosuppressants users while patients who were not on immunosuppressants within 120 days were classified as non-users. Abbreviations: COVID-19, coronavirus 2019; HIRA, Health Insurance Review and Assessment Service; KDCA, Korean Disease Control and prevention Agency. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint Figure 2 . Forest plot summarizing the Odds ratio of primary outcome associated with Immunosuppressant use compared with non-users when stratified for age, sex, history of autoimmune disease, cancer and HIV, and history of autoimmune disease. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The database used in this study is the Health Insurance Review and Assessment Service (HIRA) claim data released by the South Korean government as the world's first de-identified COVID-19 nationwide data. Since South Korea have implemented a single National Health Insurance system, this administrative data includes the entire health insurance claims and clinical information of South Korean population. Information on non-essential medical treatment that are not covered by NHI was not collected based on fee-for-service payment system. The list of patients of COVID-19 (using submitted claims data) is connected to their history of medical service use for the past 5 years (using finalized claims data, from January 2015 to February 2020), and the entire data set is de-identified. All benefit claims relevant to COVID-19 as of May 15, 2020 were included. The databased include all health insurance types such as National Health Insurance, Medical Aid, Korea veterans service. COVID19 related claims consists of i) claims with "3/02" in classification code of MT043 (Target of medical cost support due to national disaster) based on the serial number of claim statement, ii) claims that contained "D6584" COVID-19 (Real-time polymerase chain reaction), iii) claims that contained COVID-19 related disease code (B342, B972, Z208, Z290, U18, U181, Z038, Z115, U071, U072), and iv)·claims that contained other COVID-19 related fee code (COVID-19 related admission fee, management fee, IUD, isolation, public relief hospital, residential treatment center, screening center, negative pressure room, etc.). The data based consists of COVID-19 related claims data, 3years of healthcare service use history of the individuals who submitted COVID-19 related claims. COVID-19 confirmation information and some related results were extracted from KCDA database. The included information are as follows: -Sociodemographic characteristics (i.e., sex, age, medical institution type) -Diagnosis information (i.e., ICD-10 diagnosis codes, main diagnosis, sub diagnosis) -Healthcare utilization information (i.e., number of visit, date of visit, duration of hospital stay) -Prescription information (i.e., national drug chemical code, number of supply, date of supply, dosage) All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 20, 2021. ; https://doi.org/10.1101/2021.08.17.21262183 doi: medRxiv preprint Note: COVID-19, coronavirus disease 2019; ICD-10, International Classification of Disease 10 th Revision. Detailed information on data schema is available upon request. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges Severe acute respiratory syndrome-related coronavirus: The species and its viruses -a statement of the Coronavirus Study Group Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials Covid-19 -The Search for Effective Therapy COVID-19: consider cytokine storm syndromes and immunosuppression Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Update to living WHO guideline on drugs for covid-19 Dexamethasone in Hospitalized Patients with Covid-19 Republic of Korea Ministry of Health and Welfare. COVID-19 Response: Korean Government's Response System